Terminated PHASE3 INTERVENTIONAL 3-arm NCT00272987

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

A Randomized, Double Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing the Activity of Paclitaxel Plus Trastuzumab Plus Lapatinib to Paclitaxel Plus Trastuzumab Plus Placebo in Women With ErbB2 Overexpressing Metastatic Breast Cancer

Sponsor: Novartis Pharmaceuticals

Conditions Neoplasms, Breast

Interventions lapatinib paclitaxel trastuzumab

Updated 14 times since 2017 Last updated: Apr 27, 2023 Started: Dec 13, 2005 Primary completion: Jul 31, 2009 Completion: Oct 21, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Enrollment was closed after the open label stage due to poor recruitment rate (randomized stage never opened).

Other terminated trials from Novartis Pharmaceuticals

See all terminations from Novartis Pharmaceuticals

Other Neoplasms, Breast trials with similar outcome

Browse all Neoplasms, Breast trials

Listed as NCT00272987, this PHASE3 trial focuses on Neoplasms, Breast and remains terminated or withdrawn. Sponsored by Novartis Pharmaceuticals, it has been updated 14 times since 2005, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

14 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
May 2023 — Jul 2024 [monthly]

Terminated PHASE3
Dec 2021 — May 2023 [monthly]

Terminated PHASE3

▶ Show 9 earlier versions

Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3

Status: Completed → Terminated
Jan 2020 — Jan 2021 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Nov 2019 — Jan 2020 [monthly]

Active Not Recruiting PHASE3
Oct 2019 — Nov 2019 [monthly]

Active Not Recruiting PHASE3
Feb 2019 — Oct 2019 [monthly]

Active Not Recruiting PHASE3
Jun 2018 — Feb 2019 [monthly]

Active Not Recruiting PHASE3
Aug 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE3
Feb 2017 — Aug 2017 [monthly]

Active Not Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

Dec 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amarillo, United States , Arlon, Belgium , Canton, United States , Charleston, United States , Columbus, United States , Detroit, United States , Houston, United States , Jackson, United States , Joliet, United States , Liège, Belgium and 5 more locations